Core Viewpoint - STAAR Surgical Company did not receive the necessary stockholder votes to approve the merger agreement with Alcon, leading to the intention to terminate the merger agreement and remain a standalone company [1][2]. Company Overview - STAAR Surgical is the global leader in implantable phakic intraocular lenses (ICLs), focusing solely on ophthalmic surgery since 1982 [3]. - The company has designed, developed, manufactured, and marketed advanced Implantable Collamer® Lenses (ICLs) for over 30 years, utilizing proprietary biocompatible Collamer material [3]. - STAAR ICLs are clinically proven to provide safe long-term vision correction without the need for corneal tissue removal or the extraction of the eye's natural crystalline lens [3]. - The EVO ICL™ product line offers visual freedom through a quick, minimally invasive procedure, with over 3 million ICLs sold in more than 75 countries [3]. Strategic Direction - The CEO of STAAR expressed commitment to maximizing stockholder value and realizing the full potential of STAAR's innovative technology, emphasizing the company's competitive position and the quality of its EVO ICL technology [2]. - In the short term, the company will prioritize profitable sales growth and drive efficiencies through its distribution network, aiming for more extensive global use of its EVO ICL technology [2].

Core Viewpoint - STAAR Surgical Company has announced the adjournment of its Special Meeting of Stockholders regarding the Alcon merger agreement, now rescheduled for January 6, 2026, due to Alcon exercising its right under the merger agreement [1]. Company Overview - STAAR Surgical (NASDAQ: STAA) is a leader in implantable phakic intraocular lenses, providing vision correction solutions that can reduce or eliminate the need for glasses or contact lenses [2]. - The company has been focused solely on ophthalmic surgery since 1982 and has sold over 3 million ICLs in more than 75 countries [2]. - STAAR's EVO ICL™ product line offers a minimally invasive procedure for vision correction without removing corneal tissue or the eye's natural crystalline lens [2]. Merger Information - The Special Meeting of Stockholders was originally scheduled for December 19, 2025, and the record date for eligible stockholders remains October 24, 2025 [1]. - Relevant materials regarding the proposed transaction have been filed with the U.S. Securities and Exchange Commission (SEC), including a definitive proxy statement on September 16, 2025 [3].